Perioperative intravenous low-dose ketamine for neuropathic pain after major lower back surgery

A randomized, placebo-controlled study. Published in the European Journal of Pain, a multi-disciplinary, international journal that aims to be a global forum on all aspects of pain research and pain management.

Christoph Czarnetzki; Jules Desmeules; Enrico Tessitore; Antonio Faundez; Jocelyne Chabert; Youssef Daali; Roxane Fournier; Elise Dupuis-Lozeron; Christine Cedraschi; Martin Richard Tramèr

European Journal of Pain. Volume24, Issue3. March 2020, Pages 555-567. DOI: 10.1002/ejp.1507

First published: 19 November 2019

Abstract

Background

Chronic pain after major lower back surgery is frequent. We investigated in adults the effect of perioperative low-dose ketamine on neuropathic lower back pain, assessed by the DN4 questionnaire, 6 and 12 months after major lower back surgery.

Methods

In this single-centre randomized trial, 80 patients received intravenous ketamine 0.25 mg/kg preoperatively, followed by 0.25 mg kg-1 hr-1 intraoperatively, and 0.1 mg kg-1 hr-1 from 1 hr before the end of surgery until the end of recovery room stay; 80 controls received placebo.

Results

Preoperatively, 47.4% of patients in the ketamine group and 46.3% in the placebo group had neuropathic pain; 10% and 3.8%, respectively, were using strong opioids. At the end of the infusion, the median cumulative dose of ketamine was 84.8 mg (IQR 67.4-106.7) and the median plasma level was 97 ng/ml (IQR 77.9-128.0). At 6 months, 28.8% of patients in the ketamine group and 23.5% in the placebo group had neuropathic pain (absolute difference, 5.2%; 95% CI -10.7 to 21.1; p = .607). At 12 months, 26.4% of patients in the ketamine group and 17.9% in the placebo group had neuropathic pain (absolute difference 8.5%; 95% CI -6.7 to 23.6; p = .319).

Conclusions

In this patient population with a high prevalence of neuropathic lower back pain undergoing major lower back surgery, a perioperative intravenous low-dose ketamine infusion did not have an effect on the prevalence of neuropathic lower back pain at 6 or 12 months postoperatively.

Significance

We were unable to show any analgesic benefit of a short-term perioperative ketamine infusion as an adjuvant to multimodal analgesia in patients with a high prevalence of neuropathic lower back pain undergoing major back surgery. Based on these data, the widespread opinion that ketamine is universally analgesic across different pain conditions must be challenged. Clinicaltrials.gov identifier: NCT00618423